Humacyte, Inc. (HUMA) Debt Components
- 2026-06-30: Unsecured Debt, CurrentUSD (m); Long-term DebtUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Unamortized DiscountUSD (m).
- 2026-06-30: Unsecured Debt, CurrentUSD (m); Long-term DebtUSD $36.32M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Unamortized DiscountUSD $2.91M.
- 2026-03-31: Unsecured Debt, CurrentUSD (m); Long-term DebtUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Unamortized DiscountUSD (m).
- 2026-03-31: Unsecured Debt, CurrentUSD (m); Long-term DebtUSD $35.87M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Unamortized DiscountUSD $3.13M.
Humacyte, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Unsecured Debt, Current USD | Long-term Debt USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Unamortized Discount USD | Debt Instrument Issued Principal USD | Secured Debt, Current USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | (m) | 6 month · $1.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-06-30 | (m) | $36.32M | (m) | $2.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | (m) | (m) | 3 month · $1.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $35.87M | (m) | $3.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $35.44M | (m) | $3.34M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | (m) | 12 month · $1.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-15 | (m) | (m) | $77.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $3.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $2.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $1.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $885.00K | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $12.86M | $17.14M | $4.29M | (m) | (m) | $8.57M | $30.00M |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $8.57M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $8.57M | $17.14M | $4.29M | (m) | (m) | $30.00M |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $4.29M | $8.57M | $17.14M | $4.29M | (m) | $0.00 | $30.00M |
| 2022-06-30 | (m) | $30.00M | (m) | (m) | (m) | (m) | $8.57M | $17.14M | $4.29M | (m) | $0.00 | (m) |
| 2022-03-31 | (m) | $30.00M | (m) | (m) | (m) | (m) | $10.00M | $17.14M | $2.86M | (m) | $0.00 | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $30.00M | (m) | (m) | (m) | (m) | $0.00 | $10.00M | $17.14M | $2.86M | (m) | (m) |
| 2021-09-30 | (m) | $20.00M | (m) | (m) | (m) | $3.89M | $5.55M | $6.67M | $6.67M | $1.11M | (m) | (m) |
| 2020-12-31 | $2.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |